These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 22687730)

  • 21. The importance of synthetic chemistry in the pharmaceutical industry.
    Campos KR; Coleman PJ; Alvarez JC; Dreher SD; Garbaccio RM; Terrett NK; Tillyer RD; Truppo MD; Parmee ER
    Science; 2019 Jan; 363(6424):. PubMed ID: 30655413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploratory drug safety: a discovery strategy to reduce attrition in development.
    Bass AS; Cartwright ME; Mahon C; Morrison R; Snyder R; McNamara P; Bradley P; Zhou YY; Hunter J
    J Pharmacol Toxicol Methods; 2009; 60(1):69-78. PubMed ID: 19422924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery and Development of Novel Drugs.
    Erakovic Haber V; Spaventi R
    Prog Mol Subcell Biol; 2017; 55():91-104. PubMed ID: 28238036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fragment-based drug discovery: what really works. An interview with Sandy Farmer of Boehringer Ingelheim.
    Farmer S
    J Comput Aided Mol Des; 2011 Jul; 25(7):599-605. PubMed ID: 21766241
    [No Abstract]   [Full Text] [Related]  

  • 25. Application of chemistry-based functional proteomics to screening for novel drug targets.
    Yuan K; Lei Y; Huang C
    Comb Chem High Throughput Screen; 2010 Jun; 13(5):414-21. PubMed ID: 20156143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A forensic analysis of drug targets from 2000 through 2012.
    Munos B
    Clin Pharmacol Ther; 2013 Sep; 94(3):407-11. PubMed ID: 23756372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How were new medicines discovered?
    Swinney DC; Anthony J
    Nat Rev Drug Discov; 2011 Jun; 10(7):507-19. PubMed ID: 21701501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current Challenges and Potential Opportunities for the Pharmaceutical Sciences to Make Global Impact: An FIP Perspective.
    Tucker G; DeSilva B; Dressman J; Ito M; Kumamoto T; Mager D; Mahler HC; Maitland-van der Zee AH; Pauletti GM; Sasaki H; Shah V; Tang D; Ward M
    J Pharm Sci; 2016 Sep; 105(9):2489-2497. PubMed ID: 26886325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Natural products in drug discovery: present status and perspectives.
    Molinari G
    Adv Exp Med Biol; 2009; 655():13-27. PubMed ID: 20047031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improving lead generation success through integrated methods: transcending 'drug discovery by numbers'.
    Campbell JB
    IDrugs; 2010 Dec; 13(12):874-9. PubMed ID: 21154146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-throughput in vitro profiling assays: lessons learnt from experiences at Novartis.
    Faller B; Wang J; Zimmerlin A; Bell L; Hamon J; Whitebread S; Azzaoui K; Bojanic D; Urban L
    Expert Opin Drug Metab Toxicol; 2006 Dec; 2(6):823-33. PubMed ID: 17125403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overview of drug discovery and development.
    Ator MA; Mallamo JP; Williams M
    Curr Protoc Pharmacol; 2006 Dec; Chapter 9():Unit9.9. PubMed ID: 22294181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Organs-on-chips at the frontiers of drug discovery.
    Esch EW; Bahinski A; Huh D
    Nat Rev Drug Discov; 2015 Apr; 14(4):248-60. PubMed ID: 25792263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A practical guide to secondary pharmacology in drug discovery.
    Jenkinson S; Schmidt F; Rosenbrier Ribeiro L; Delaunois A; Valentin JP
    J Pharmacol Toxicol Methods; 2020 Sep; 105():106869. PubMed ID: 32302774
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
    Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
    Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The development of medicines for older adults: A personal perspective from industry.
    Hakes L
    Int J Pharm; 2016 Oct; 512(2):332-333. PubMed ID: 26688042
    [No Abstract]   [Full Text] [Related]  

  • 37. Systems pharmacology to predict drug safety in drug development.
    Trame MN; Biliouris K; Lesko LJ; Mettetal JT
    Eur J Pharm Sci; 2016 Oct; 94():93-95. PubMed ID: 27251780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluorescence-based high-throughput screening assay for drug interactions with UGT1A6.
    Soikkeli A; Kurkela M; Hirvonen J; Yliperttula M; Finel M
    Assay Drug Dev Technol; 2011 Oct; 9(5):496-502. PubMed ID: 21438674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Establishment of novel therapeutic technologies by the fusion of medical technologies in various fields].
    Suzuki R
    Yakugaku Zasshi; 2010 Dec; 130(12):1663-4. PubMed ID: 21139392
    [No Abstract]   [Full Text] [Related]  

  • 40. Impact of modeling and simulation: myth or fact?
    Allerheiligen SR
    Clin Pharmacol Ther; 2014 Oct; 96(4):413-5. PubMed ID: 25236663
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.